Trastuzumab [180288-69-1]
Katalog-Nummer HY-P9907-25mg
Size : 25mg
Marke : MedChemExpress
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
CAS. Nr. : 180288-69-1
This product is a controlled substance and not for sale in your territory.
Based on 27 publication(s) in Google Scholar
Other Forms of Trastuzumab:
- Trastuzumab (anti-HER2) In-stock
Alle Radionuclide-Drug Conjugates (RDCs) Isoform-spezifische Produkte anzeigen:
Alle EGFR Isoform-spezifische Produkte anzeigen:
Beschreibung |
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. |
||
---|---|---|---|
Isotype |
Human IgG1 kappa |
||
Recommend Isotype Controls |
Human IgG1 kappa, Isotype Control |
||
Species |
Humanized |
||
IC50 & Target[1] |
|
||
In Vitro |
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||
In Vivo |
Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||
Klinische Studie |
|
||
CAS. Nr. |
180288-69-1 |
||
Appearance |
Solid |
||
Color |
White to light yellow |
||
SMILES |
[Trastuzumab] |
||
Speicherung |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||
Format |
|
||
Biological Activity |
|
||
Reinheit & Dokumentation |
Purity: 99.80% |
||
Verweise |
|
Trastuzumab Related Classifications
- Cancer
- Cancer Targeted Therapy Cancer Immunotherapy Cancer Drug Resistance
- Inhibitory Antibodies
- JAK/STAT Signaling Protein Tyrosine Kinase/RTK Antibody-drug Conjugate/ADC Related
- Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody